Inovio Pharmaceuticals (MEX:INO) Dividends per Share : MXN0.00 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inovio Pharmaceuticals Dividends per Share?

Inovio Pharmaceuticals's dividends per share for the three months ended in Dec. 2024 was MXN0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Inovio Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Inovio Pharmaceuticals Dividends per Share Historical Data

The historical data trend for Inovio Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Dividends per Share Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Inovio Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inovio Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Inovio Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inovio Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Dividend Yield % falls into.

Save Embed

Inovio Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Inovio Pharmaceuticals (MEX:INO) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Inovio Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-14.652
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Inovio Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (MEX:INO) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

INO:USA 0A43:UK GBM:Germany GBM:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.